Modified Bacteriophage Broad-Spectrum Antibacterial Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing antibiotic resistance among bacteria, particularly the ESKAPE pathogens, poses a significant challenge in treating bacterial infections, as current antibiotics are ineffective against multi-drug resistant strains like Pseudomonas aeruginosa, leading to high mortality rates and a need for novel antibacterial agents.
Innovation Solution
A modified bacteriophage is developed that is capable of infecting a variety of bacterial species, incorporating a toxin gene and expressing host range determinant proteins with multiple bacterial specificities, allowing it to be engineered for broad-spectrum antibacterial activity and manufactured in a host cell for effective use as an antibacterial agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional non-lytic SASPject vectors are used, then bacterial toxicity is achieved, but lower doses require more frequent administration and higher overall dosing is needed
Solution Approach 1:
The patent transitions from static non-lytic vectors to dynamic lytic vectors that actively replicate and lyse bacterial cells, enabling self-amplification and sustained bacterial exposure to SASP toxin, thereby reducing required dose frequency
Solution Approach 2:
The lytic bacteriophage vector replicates within bacterial cells and lyses them to release progeny phages that continue the killing process, creating a self-sustaining therapeutic effect that reduces the need for repeated high-dose administrations
2Adaptability or versatility
If broad-spectrum antibacterial activity is achieved through multiple HRD proteins, then host range is improved, but device complexity increases
Solution Approach 1:
The patent incorporates multiple host range determinant (HRD) proteins into a single bacteriophage vector, enabling one phage to recognize and infect multiple different bacterial species through its tail fiber proteins, thereby achieving broad-spectrum activity without requiring multiple separate phage preparations
Solution Approach 2:
The patent combines multiple HRD genes from different bacteriophages into a single genetic construct that can be co-expressed in the engineered lytic bacteriophage, merging the host recognition capabilities of multiple phages into one unified vector system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified bacteriophage demonstrates enhanced host range and potency, capable of replicating and producing toxic levels of SASP protein within bacterial cells, effectively reducing bacterial viability and showing promise in treating infections with lower doses compared to traditional non-lytic SASPject vectors.
Implementation Method 1
the modified bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant (HRD) proteins which have a plurality of bacterial host specificities
Implementation Method 2
the bacteriophage expresses host range determinant (HRD) proteins which have a plurality of bacterial host specificities
Implementation Method 3
incorporating a toxin gene and expressing host range determinant proteins with multiple bacterial specificities, allowing it to be engineered for broad-spectrum antibacterial activity
Data Source
AI summary
A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria; wherein the bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.